CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen-Reference-Cited by-同舟云学术

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

Published:2010-08 Issue:4 Volume:12 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Abraham Jean E,Maranian Mel J,Driver Kristy E,Platte Radka,Kalmyrzaev Bolot,Baynes Caroline,Luccarini Craig,Shah Mitul,Ingle Susan,Greenberg David,Earl Helena M,Dunning Alison M,Pharoah Paul DP,Caldas Carlos

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr2629.pdf

Reference50 articles.

1. Ingle J: Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer. 2008, 112: 695-699. 10.1002/cncr.23192.

2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.

3. Robertson DW, Kattzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS: Tamoxifen antiestrogens: a comparison of the activity, pharmacokinetics and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem. 1982, 16: 1-13. 10.1016/0022-4731(82)90137-6.

4. Jordan VC: Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance. Breast Cancer Res Treat. 1982, 2: 123-138. 10.1007/BF01806449.

5. Wakeling AE, Slater SR: Estrogen-receptor binding and biological activity of tamoxifen and its metabolites. Cancer Treat Rep. 1980, 64: 741-744.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data;Clinical and Translational Science;2024-03

2. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer;Journal of Pharmaceutical and Biomedical Analysis;2024-01

3. Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen;Frontiers in Oncology;2022-02-17

4. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis;Expert Reviews in Molecular Medicine;2022

5. Predictive Biomarkers for Anticancer Drugs;Cancer Biomarkers in Diagnosis and Therapeutics;2022